Fig. 1.

Combinatory CCL16/CpG +anti-IL-10R mAb treatment cures mice from orthotopic prostate tumors. a Left panels percentage of tumor-free mice after intra-prostatic T1525p tumor cell injection and subsequent treatment (TC combination, untreated control and single-agent comparison is shown in the upper panel, and TC combination, untreated control and other combination treatments in the lower panel); difference in percentage of mice with regressing tumor between TC and all the other treatments is statistically significant: p < 0.005; right panels: mean tumor volume from the same samples; cumulative results of two to three independent experiments are shown; the total number of mice is indicated in the right panels. Mice with regressing tumor became completely tumor free in 15–20 days and remained as such for the whole observation period, at least 80–100 days. b Representative ventral visions of 3-D rendering volumes from ultrasound images of tumors at the time of second (+10 days) treatment and their follow-up to day 40. All mice were injected intra-prostate on day 0 with 2 × 10⁶ T1525p cells, and 10 days later, the tumor injected locally with the aid of ultrasound-guide with the indicated agents in combination or not. Examples from two TC-treated mice and from one mouse treated with control adenoviral vector + CpG + IL-10R mAb and one treated with AdCCL16 + IL-10R mAb. Red zone indicates the tumor volume